<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Reproductive Health Access Project</provider_name><provider_url>https://www.reproductiveaccess.org</provider_url><author_name>Brandy Bautista</author_name><author_url>https://www.reproductiveaccess.org/author/brandy/</author_url><title>Insights: Letrozole and Early Miscarriage Management - Reproductive Health Access Project</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="aAh9lcCXPc"&gt;&lt;a href="https://www.reproductiveaccess.org/resource/insights-letrozole-and-early-miscarriage-management/"&gt;Insights: Letrozole and Early Miscarriage Management&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.reproductiveaccess.org/resource/insights-letrozole-and-early-miscarriage-management/embed/#?secret=aAh9lcCXPc" width="600" height="338" title="&#x201C;Insights: Letrozole and Early Miscarriage Management&#x201D; &#x2014; Reproductive Health Access Project" data-secret="aAh9lcCXPc" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>Written by Kenya Lyons, MD The administration of mifepristone followed by misoprostol is a highly effective regimen for the management of first-trimester miscarriage and medication abortion.1 However, even prior to the onset of legal challenges to mifepristone, including FDA v. Alliance for Hippocratic Medicine, the search for alternative therapies existed. This has been driven by&hellip;</description><thumbnail_url>https://www.reproductiveaccess.org/wp-content/uploads/2015/02/email-banner-logo-rhap.jpg</thumbnail_url><thumbnail_width>250</thumbnail_width><thumbnail_height>118</thumbnail_height></oembed>
